MASH Drug Pipeline Accelerates With Approvals and Smarter Clinical Trials

Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, is the progressive inflammatory form of fatty liver disease and a leading driver of cirrhosis and liver transplantation globally. With no approved treatments for decades, the field is now experiencing a pivotal transformation in both drug availability and trial design.

This review by Dunn and Alkhouri surveys the current therapeutic landscape, highlighting that resmetirom (a thyroid hormone receptor-beta agonist) and semaglutide (a GLP-1 receptor agonist) have each received accelerated FDA approval for MASH based on histological improvements — specifically reductions in liver inflammation and fibrosis — in patients without cirrhosis. These approvals mark a watershed moment for the field.

Beyond these initial successes, the authors examine the frontier of cirrhosis-stage trials, which are inherently more challenging. Unlike earlier-stage disease, cirrhosis trials require event-driven designs that track hard clinical endpoints such as liver decompensation, hepatocellular carcinoma, transplantation, or death — outcomes that take years to accumulate and demand larger populations.

To streamline this process, the field is embracing noninvasive biomarkers (such as imaging-based fibrosis scores and blood-based assays) as surrogate endpoints, reducing reliance on liver biopsy. Hybrid endpoints combining both surrogate and clinical markers are also gaining traction. Combination therapies targeting complementary mechanisms — metabolic, inflammatory, and fibrotic — represent another major strategic direction.

A key caveat is that this is a perspective or review article rather than original clinical trial data, limiting the strength of its conclusions. The authors also carry significant industry relationships across competing drug developers, warranting consideration of potential bias when interpreting their framing of the evidence.